Veterans and Psilocybin: The Neuroscience of Healing the Wounds of War

22 veterans die by suicide every day. The Department of Veterans Affairs has documented more than 6,000 veteran suicides every year for more than twenty years — an age- and sex-adjusted rate approximately twice that of non-veteran US adults. The April 2026 presidential fact sheet accompanying the federal psychedelic research executive order stated the pattern plainly. Two decades. Six thousand a year. Twenty-two a day. A crisis at population scale with no precedent in modern American military history outside of the wartime casualty count itself.

The standard of care has not closed this gap. The sertraline registration trial published by Brady and colleagues in JAMA in 2000 — still the pharmacological foundation of VA PTSD prescribing — produced a 53 percent response rate against 32 percent placebo, but only 20 to 30 percent full remission, and meta-analytic work has consistently shown veterans recover smaller SSRI effect sizes than civilians. Prolonged Exposure and Cognitive Processing Therapy show outpatient dropout in the 38.5 percent range in Kehle-Forbes’ VA cohort, climbing to 56 percent for PE and 47 percent for CPT in a veteran RCT, and to 65 percent in another. A trajectory analysis identified roughly 27.5 percent of treated veterans as belonging to a non-response class showing little change across multiple adequate trials. Nearly one in four US veterans now screens positive for probable traumatic brain injury, compounding every downstream complication that follows.

This article concerns a single empirical question. Standard psychiatric care intervenes at one node — serotonin reuptake, fear-memory exposure, cognitive restructuring — and asks the rest of the system to follow. Combat trauma damages four neural systems simultaneously: an amygdala recalibrated upward into permanent hypervigilance, a default mode network locked around a self-narrative organized by what happened in theater, a fear-extinction circuit whose infralimbic-to-basolateral synaptic plasticity has degraded, and a microglial neuroimmune compartment primed by years of HPA-axis dysregulation. The thesis assembled here, drawing on more than two dozen peer-reviewed mechanism papers and the first VA-conducted veteran trials to reach publication, is that psilocybin is the first pharmacological intervention demonstrated to engage all four of those systems in a single dose. That four-mechanism convergence is what the rest of this article examines.

The Crisis Standard Treatments Cannot Reach

The structural failure rates in veteran PTSD care reflect a mismatch between what current treatments target and what combat trauma actually breaks. Sertraline, paroxetine, and venlafaxine — the only agents with FDA labeling or VA/DoD guideline endorsement for PTSD — produce their effect through tonic SERT blockade and downstream receptor adaptation. They do not directly restore prefrontal authority over the amygdala, do not enhance fear-extinction learning, do not reconfigure the default mode network’s coupling to autobiographical memory, and do not modulate microglial activation. Sun and colleagues’ 2022 systematic review of 22 RCTs in combat-related PTSD found that, among monotherapy options, only atypical antipsychotic augmentation showed superior efficacy to placebo. SSRIs, the field’s default, did not.

Prolonged Exposure and Cognitive Processing Therapy target a different layer: the failure of fear-extinction learning to generalize and persist. In veterans, the dropout rates outpace the response rates. Kehle-Forbes and colleagues found 38.5 percent overall PE dropout in VA outpatient settings; in some combat-veteran RCTs the figure rises to 56 percent for PE and as high as 65 percent in others. Roughly thirty percent of veterans who initiate PE complete fewer than the eight sessions that constitute the minimum therapeutic dose. Modality matters — Acierno’s work showed sixty percent dropout from office-telehealth, forty-four percent from home-telehealth, and twenty-six percent from in-home in-person — but no delivery format brings the failure rate below the threshold at which most clinicians would consider it reliable. Comorbid major depression raises attrition above 38 percent independently.

The polypharmacy trap follows. A veteran failing first-line sertraline is moved to a second SSRI; failing that, to mirtazapine, prazosin for nightmares, an atypical antipsychotic for hyperarousal, often a benzodiazepine despite guidelines, and frequently an opioid for comorbid chronic pain. The 27.5 percent treatment-resistant trajectory class identified by Stein’s group represents the population for whom this stack has been tried, failed, and often produced its own iatrogenic burden. The mild TBI population on top of all of this shows particularly high rates of PTSD, headache, depression, and sleep disorder co-occurrence. The mechanistic reading is direct: current treatments touch one to two of the four systems combat trauma damages, do so chronically rather than via discrete plasticity windows, and produce attrition rates that systematically remove the most severely affected veterans from the care pipeline.

Mechanism One: Resetting Amygdala Hyperreactivity

The amygdala signature in combat PTSD is the cleanest finding in trauma neuroscience: chronic hyperreactivity to threat-relevant stimuli, blunted habituation, and loss of top-down inhibition from ventromedial prefrontal cortex. Kraehenmann and Vollenweider’s 2015 study in Biological Psychiatry provided the first direct human neuroimaging evidence that psilocybin acutely modulates this circuit. A single 0.16 mg/kg dose attenuated right amygdala BOLD response to negative and neutral faces in healthy volunteers, with the magnitude of attenuation correlating with positive-mood induction. Bhattacharyya’s 2025 acute-fMRI replication in 26 healthy adults confirmed the signature: amygdala response to angry faces was significantly reduced during active psilocybin, and subjective intensity correlated inversely with amygdala reactivity to fearful faces.

What distinguishes psilocybin from SSRIs is what happens next. Roseman, Carhart-Harris and colleagues’ 2018 Neuropharmacology paper followed 19 treatment-resistant depression patients through two psilocybin sessions and rescanned them one day after the second dose. Counter to the acute signature, post-treatment amygdala BOLD response to fearful faces had increased, and the magnitude of the increase predicted positive clinical outcome at one week. SSRIs do not produce this profile. Tonic serotonin reuptake blockade chronically blunts amygdala reactivity, and the blunting is tied to the emotional flattening the Oxford Depression Questionnaire reliably detects. Mertens, Roseman, Carhart-Harris and colleagues’ 2020 Journal of Psychopharmacology paper extended the finding to the regulatory circuitry: post-treatment amygdala–ventromedial prefrontal functional connectivity during emotional processing recovered toward a more adaptive configuration — prefrontal authority re-asserted, amygdala engagement restored without chronic suppression.

The dual signature — acute damping that permits trauma exposure without overwhelm, followed by post-treatment recalibration that restores rather than abolishes affective engagement — is unique to 5-HT2A psychedelics. It is what the PTSD-specific neuroimaging literature has begun to call a re-opening of emotional bandwidth rather than a flattening of it. For combat PTSD, in which amygdala-driven hypervigilance persists for decades after deployment and constitutes the daily experiential signature of the disorder, this is the difference between a drug that suppresses an alarm and a drug that recalibrates the alarm system.

Mechanism Two: Default Mode Network Repair

The default mode network — anchored at medial prefrontal cortex, posterior cingulate, precuneus, and angular gyrus, with deep coupling to anterior hippocampus — is the substrate of self-referential cognition, autobiographical memory, and the narrative continuity of personal identity. Bluhm and colleagues’ 2009 paper in the Journal of Psychiatry and Neuroscience was the first demonstration that this network’s resting-state architecture is disrupted in PTSD: reduced PCC–precuneus–mPFC connectivity, with greater symptom severity tracking greater connectivity loss. The decade of work that followed, much of it from Lanius and Daniels’ group, established the broader picture. PTSD involves DMN hyperconnectivity to the salience network, driving rumination and intrusive symptoms; decoupling from the central executive network, undermining cognitive control; and pathological DMN-anterior hippocampus coupling around trauma memories. Akiki and colleagues’ 2018 network-restricted topology analysis in Neuropsychopharmacology confirmed DMN abnormalities are central to PTSD architecture.

The clinical phenomenology that emerges is the trauma narrative itself: the world is dangerous, I am damaged, the trauma is who I am now. In moral-injury cases the narrative extends further: I am the act I committed, I am what I failed to prevent. These are high-precision, slowly-updating priors encoded across DMN architecture — exactly the substrate REBUS, the Relaxed Beliefs Under pSychedelics model proposed by Carhart-Harris and Friston in their 2019 Pharmacological Reviews paper, predicts 5-HT2A agonism will most directly loosen.

Carhart-Harris and colleagues’ 2012 PNAS paper was the first fMRI evidence that acute psilocybin disrupts DMN integrity, reducing mPFC–PCC connectivity in dose-dependent fashion. The Siegel, Dosenbach and colleagues study published in Nature in 2024 took the question to a different methodological level. Using precision functional mapping with up to 17 MRI visits per participant before, during, and up to three weeks after dosing — with six-month follow-up — they showed psilocybin produced acute network changes more than three times larger than methylphenidate, and that one specific connectivity finding persisted for weeks: a sustained decrease in functional connectivity between the anterior hippocampus and the DMN cortex, normalizing only by the six-month timepoint. Individual differences in the magnitude of change correlated with the subjective intensity of the experience.

The bridging logic for combat PTSD and for moral injury and grief in veterans is direct. PTSD is, among other things, a disorder of pathological DMN-anterior hippocampus over-coupling around trauma memory. The trauma is bound too tightly to the autobiographical self; the self cannot be retrieved without the trauma being retrieved with it. The Siegel finding is the structural correlate of what veterans across the open-label trials describe: a temporary loosening of the identification between self and event that permits, for the first time in years, a reorganization of the narrative. The pharmacology creates the window. The integration work fills it.

Mechanism Three: Rebuilding the Fear-Extinction Circuit

PTSD is, at the circuit level, a failure of fear extinction. Pavlovian fear conditioning encodes threat associations rapidly through the amygdala; extinction learning encodes safety associations more slowly through glutamatergic projections from infralimbic prefrontal cortex onto inhibitory interneurons in the basolateral amygdala. The Rauch, Shin and Phelps neurocircuitry model — extended by Milad and Quirk’s work on infralimbic plasticity — established that PTSD is not a failure to acquire fear but a failure to extinguish it. The IL-BLA synapse is where that failure lives. PE and CPT work, when they work, by driving extinction learning through repeated controlled re-exposure. They cannot restore the underlying synaptic plasticity that extinction requires when chronic stress, sleep deprivation, and combat-zone HPA dysregulation have degraded it.

Catlow and colleagues’ 2013 paper in Experimental Brain Research was the foundational rodent demonstration that psilocybin reaches this layer. Low-dose psilocybin (0.1 mg/kg) enhanced extinction of trace fear conditioning in mice and produced a trend toward increased BrdU-positive cells in the hippocampal dentate gyrus. Critically, pretreatment with the 5-HT2A antagonist ketanserin abolished the effect, establishing receptor dependence. Hibicke and Nichols’ 2025 paper in ACS Pharmacology and Translational Science demonstrated the property that matters most for veterans: psilocybin enhanced cued fear extinction and extinction recall in stress-naïve, acutely stressed, and chronically stressed mice — across the full range of stress states most analogous to the combat-veteran population. De Gregorio and colleagues’ 2024 paper in ACS Chemical Neuroscience formalized the conditions: dose- and context-dependent, requiring concurrent extinction experience, blocked by 5-HT2A antagonism. The window is real; the window requires the learning to occur within it.

The cellular substrate underneath is now characterized in striking detail. Shao, Liston and colleagues’ 2021 paper in Neuron used two-photon imaging in awake mice to show that a single dose of psilocybin produced an approximately ten percent increase in dendritic spine density and head size in layer V pyramidal neurons of medial frontal cortex within 24 hours, persisting at least one month. Ly, Olson and colleagues’ 2018 paper in Cell Reports established the broader principle — psychedelics promote rapid and persistent structural and functional neural plasticity through 5-HT2A activation, with downstream BDNF and TrkB signaling — and Moliner and colleagues’ 2023 Nature Neuroscience paper closed the loop by demonstrating direct TrkB binding independent of 5-HT2A. The IL-BLA synapse cannot extinguish what it cannot plastically encode; the cortical microcircuitry now has measurable evidence of a 24-hour-to-one-month structural plasticity window the right therapeutic container can use. The convergence with the foundational mechanism literature on veteran-specific psilocybin therapy is direct.

Mechanism Four: Quieting the Neuroinflammatory Storm and the Moral Injury Question

The fourth system combat trauma damages is the one the first three obscure. Chronic combat stress drives sustained HPA-axis dysregulation, which over months and years primes microglia toward an M1 pro-inflammatory phenotype. The downstream profile in symptomatic veterans includes elevated peripheral C-reactive protein and IL-6, elevated central TNF-α, IL-6 and IL-1β, and PET evidence of microglial activation in regions implicated in PTSD and depression. Microglial activation drives central sensitization of pain, disrupts sleep architecture, generates the constant low-grade physical wrongness veterans describe, and feeds back onto mood circuitry to produce the depression-like phenotype that comorbidly tracks PTSD in roughly half the treatment-seeking population. This is one mechanism by which chronic pain becomes biologically inseparable from PTSD in veterans — a mechanism no SSRI, no SNRI, and no exposure protocol directly addresses.

Flanagan, Nichols and colleagues’ 2024 paper demonstrated that psilocin — psilocybin’s active metabolite — modulates microglial neuroimmune function via 5-HT2 receptor signaling, suppressing LPS-induced TNF-α and IL-1β release in primary microglia. Kozlowska and colleagues’ 2026 paper in Pharmacological Reports showed reduced microglial activation in rat spinal cord under chronic mild stress treated with psilocybin. 2025 work in International Immunopharmacology mapped the pathway: psilocybin and psilocin engage both serotonergic and aryl hydrocarbon receptor (AhR) signaling, with AhR activation specifically required for BDNF upregulation and the 5-HT2A/2B/7 plus TrkB axis driving TNF-α suppression. Qureshi and colleagues’ 2024 review in the British Journal of Pharmacology synthesized the picture: psychedelics suppress NF-κB downstream cytokine cascade.

The clinical convergence with moral injury makes this mechanism more than peripheral. Litz’s 2009 framework in Clinical Psychology Review distinguished moral injury — guilt, shame, and self-revulsion arising from violations of one’s own moral code in combat — from fear-based PTSD. Prevalence work suggests 25 to 50 percent of combat veterans carry significant moral injury. Sun and colleagues’ 2019 resting-state fMRI work dissociated moral injury from PTSD at the level of brain architecture: moral injury uniquely involves precuneus, posterior cingulate, and medial prefrontal dysregulation — the DMN, not the amygdala. Yan, Pietrzak and colleagues’ 2023 analysis of the National Health and Resilience in Veterans Study confirmed that moral injury independently predicts substance use disorder comorbidity in combat veterans.

This is why SSRIs do not reach moral injury, and why exposure-based psychotherapies, calibrated to the fear circuit, also do not. Moral injury is a DMN-encoded self-narrative disorder, and the DMN is the network psilocybin most profoundly and durably uncouples. Combined with veteran-relevant anxiety, shame and self-referential rumination that REBUS predicts will loosen under acute 5-HT2A agonism, and Roseman’s documentation of oxytocin-linked feelings of connection in the post-acute window, psilocybin becomes the only known pharmacological intervention with a plausible mechanistic claim on the moral-injury substrate. The mechanistic claim is not yet a clinical efficacy claim. But the substrate alignment is real.

What the Clinical Data Show

The veteran-specific clinical evidence remains earlier-stage than the mechanism literature. The most direct dataset published to date is the Mount Sinai/James J. Peters VAMC open-label psilocybin trial in severely treatment-resistant veterans, published in the Journal of Affective Disorders in December 2025. Following a single 25 mg dose, 60 percent of participants met response criteria and 53 percent met remission criteria at three weeks; 47 percent and 40 percent maintained those thresholds at twelve weeks. Rachel Yehuda’s group at Mount Sinai, supported by a Bob and Renee Parsons Foundation grant since 2021, now leads the principal site in a nine-facility VA network announced in November 2025 — Bronx, Los Angeles, Omaha, Palo Alto, Portland (Oregon), San Diego, San Francisco, West Haven, and White River Junction — covering both MDMA and psilocybin protocols.

The largest peer-reviewed observational dataset in veterans comes from the Heroic Hearts Project collaboration with Imperial College London, King’s College London, Edinburgh, and UCSF Neuroscape, published in 2025 in Brain and Behavior. Across 58 US and UK veterans attending psilocybin or ayahuasca retreats between 2021 and 2024, depression scores fell 29 percent and PTSD symptom scores 26 percent, with significant improvements in anxiety, sleep, post-concussion symptoms, quality of life, and reintegration. A 21-veteran sub-study in Frontiers in Psychiatry documented EEG normalization of disrupted spontaneous patterns in emotional processing and cognitive control regions. The observational design does not substitute for randomized data, but the consistency of direction across measures and the EEG biomarker corroboration carry signal not easily dismissed.

The proximate signal in the most severely affected veteran subpopulation comes from Nolan Williams’ Stanford-affiliated group with VETS Inc., published in Nature Medicine in January 2024. Thirty special-operations veterans with TBI and blast exposure who underwent magnesium-ibogaine therapy in Mexico showed an 88 percent reduction in PTSD symptoms, 87 percent in depression, and 81 percent in anxiety at one month, with WHODAS disability scores falling from 30.2 to 5.1. The compound is ibogaine rather than psilocybin — but the demonstration that a single psychedelic intervention can produce that magnitude of change in the most TBI-laden combat veteran subpopulation is the proximate signal the broader field has been waiting for.

The depression-side evidence relevant to the highly comorbid veteran TRD population is now Phase 3. COMPASS Pathways’ COMP005 (N=258, 32 US sites) hit its primary endpoint with p<0.001 and a MADRS difference of −3.6; COMP006, the two-dose follow-on, hit p<0.001 with −3.8 MADRS difference and durability past 26 weeks in responders. The Mitchell MAPS Phase 3 MDMA-PTSD trials (MAPP1, MAPP2) reported 67 and 71 percent of treated participants no longer meeting PTSD criteria — figures widely extrapolated to the veteran psilocybin context but, as the Phase 3 depression-trial review notes, derived from civilian-majority samples. The Lykos Complete Response Letter issued by FDA in August 2024 cited functional unblinding, expectancy effects, and safety-monitoring concerns, and the recommendation of an additional Phase 3 has reset the MDMA timeline. Psilocybin’s path may now overtake MDMA’s in the veteran population — but the explicit gap remains: no large veteran-specific psilocybin-PTSD RCT has yet published, and most “67 percent” type claims for veterans-with-psilocybin currently extrapolate.

The Regulatory Pathway Has Opened

The regulatory environment is no longer the limiting factor. The FY24 National Defense Authorization Act, signed December 2023, included a bipartisan provision led by Representative Morgan Luttrell — a Navy SEAL veteran who has publicly described his own psychedelic-assisted therapy — co-sponsored by Crenshaw, Khanna, and Ocasio-Cortez, allocating $10 million and requiring DoD to establish a process by which active-duty service members with PTSD or TBI can participate in psychedelic trials including psilocybin, MDMA, ibogaine, DMT, and ayahuasca. The April 2026 executive order “Accelerating Medical Treatments for Serious Mental Illness” allocates a minimum of $50 million from HHS, mandates HHS-FDA-VA collaboration on trial participation, data sharing, and real-world evidence, and prioritizes Breakthrough Therapy designees — currently including COMPASS’s COMP360 and Usona Institute’s PSIL201. The PATH Caucus Innovative Therapies Centers of Excellence Act, advanced by Correa, Bergman, Crenshaw, Luttrell and Khanna, would allocate $30 million annually for at least five VA centers of excellence.

At the state level, Oregon’s Measure 109, operational since 2023, has supported Heroic Hearts’ eight veteran cohorts through licensed service centers — the first US-legal veteran psilocybin access pathway. Colorado’s Proposition 122, with healing centers operational since January 2025, codified reduced facilitator licensing fees and reduced service fees for veterans and low-income individuals. The Veterans of Foreign Wars and Disabled American Veterans have publicly endorsed the federal trajectory. None of this constitutes approval; all of it constitutes a research and access infrastructure that did not meaningfully exist in 2022.

Why OOTW Launched ootwveterans.com

The OOTW team had been publishing the underlying neuroscience for two years by the time the 22-a-day number became unignorable. The veteran piece kept resurfacing across the journal: the foundational veterans-and-psilocybin mechanism article, the PTSD evidence synthesis, the depression Phase 3 review, the grief and prolonged bereavement work directly relevant to surviving units and gold-star families, the chronic pain piece covering the population where TBI, pain and PTSD converge into opioid prescribing, and the anxiety overview covering the post-deployment GAD and panic spectrum. The same mechanism convergence kept showing up across the literature.

The decision to build ootwveterans.com followed from a single observation: the people who most need this synthesis — veterans, families of veterans, clinicians serving them, and the public actors whose votes and budgets shape the regulatory landscape — were arriving at the science through fragmented channels. A dedicated entry point made sense not as a separate brand but as a focused doorway to the same evidence base, oriented to a population whose mechanism profile, comorbidity stack, and treatment history is distinct enough to warrant its own portal. What ootwveterans.com is: an evidence-curated portal pointing to the major peer-reviewed papers cited throughout this article, the clinical trials currently accepting enrollment through ClinicalTrials.gov, and the established support organizations including Heroic Hearts Project, VETS Inc., and Mission Within. What ootwveterans.com is not: a clinic, a retreat operator, a vendor, or a referral broker. OOTW remains a chocolate company that runs a peer-reviewed-science journal. The veterans portal points to the field’s resources. It does not point back to us.

The 22-a-day figure will keep declining only if the science keeps surfacing — if the mechanism literature reaches the clinicians prescribing the SSRIs, if the Phase 3 readouts reach the legislators writing the appropriations, if the trial network reaches the veterans who have aged out of PE and CPT and have nowhere else to go. Publishing the synthesis is what we can do with the platform we have built.

What the Science Has Not Yet Proven

The case advanced here rests on a four-mechanism convergence documented across more than two dozen peer-reviewed papers and replicated across multiple laboratories. It does not yet rest on a large veteran-specific psilocybin-PTSD randomized controlled trial, because no such trial has yet published. The Mount Sinai open-label dataset, the Heroic Hearts retreat data, and the multi-site nine-VA-facility expansion are the closest available substitutes; they are not equivalent. Moral injury is rarely captured as a separable outcome — the MISS-M has not yet become a standard endpoint. Data on how long-term-medicated veterans respond to psilocybin after SSRI taper, given Gukasyan’s documentation of persistent attenuation of psilocybin experience in chronic SSRI users, remains thin. The Heroic Hearts EEG sub-study is encouraging but small, and safety in moderate-to-severe TBI rather than mild TBI is not established. Long-term durability beyond twelve months awaits the Mount Sinai 2026 and 2027 follow-ups. The science is convergent. In the veteran population specifically, it is not yet conclusive.